AID |
Autoimmune diseases |
ANA |
Antinuclear antibody |
Anti-CCP |
Anti-cyclic citrullinated peptide |
ASIA |
Autoimmune/Inflammatory syndrome induced by adjuvants |
ASMA |
Anti-smooth muscle antibody |
CI |
Confidence interval |
CPI |
Check-point inhibitors |
CTLA |
Cytotoxic T lymphocyte antigen |
ENA |
Extractable nuclear antigens |
HBV |
Hepatitis B virus |
HLA |
Human leukocyte antigen |
ICIs |
Immune checkpoint inhibitors |
IFN-γ |
Interferon gamma |
IL |
Interleukin |
irAEs |
Immune-related adverse events |
NZB |
New Zealand black |
NZM |
New Zealand mixed |
OR |
Odds ratio |
PD-1 |
Programmed cell death receptor-1 |
PFS |
Progression free survival |
RF |
Rheumatoid factor |
SADs |
Systemic autoimmune diseases |
SBIs |
Silicone breast implants |
SFN |
Small fiber neuropathy |
SIIS |
Silicone implant incompatibility syndrome |
SS |
Sjogren’s syndrome |
SSc |
Systemic sclerosis |
TGF-β |
Transforming growth factor β |
Th |
T helper lymphocytes |
TLR-4 |
Toll-like receptor 4 |
TNF-α |
Tumor necrosis factor α |
UCTD |
Undifferentiated connective tissue disease |